Dr. med. Dirk Manski

 You are here: Urology Textbook > Drugs in Urology > Alpha blocker > Alfuzosin

Alfuzosin: Side Effects and Dosage

Mechanism of Action of Alfuzosin

Alfuzosin is a nonselective α1-blocker with short elimination half-life; sustained-release formulation is available. Please see section general pharmacology of alpha blocker. Review Literatur: (Chapple, 2004).

figure structural formula of alfuzosin
Structural formula of Alfuzosin

Indications for Alfuzosin

Pharmacokinetics of Alfuzosin

Elimination half-life: 9 h for the sustained-release formulation.

Side Effects

Increased side effect profile, since alfuzosin is a nonselective α1 blocker.

Contraindications of Alfuzosin

Urological Contraindications:

Conservative treatment of BPH is not indicated if surgical treatment is imperative: chronic urinary retention with renal failure, recurrent hematuria due to prostatic enlargement, recurrent infections, and bladder stones.

Cardiac Contraindications:

Hypotension, mechanical heart failure (valvular, pulmonary embolism, pericarditis), congestive heart failure.

Other contraindications:

Alfuzosin should be paused for cataract surgery to prevent an intraoperative floppy iris syndrome.

Dosage of Alfuzosin

10 mg in retarded galenic formulation orally once daily or 5 mg 1–0–1. The initial or single dose should be given before bedtime in the evening to reduce side effects.

Index: 1–9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z


Chapple 2004 CHAPPLE, C. R.: Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician.
In: BJU Int
94 (2004), Nr. 5, S. 738–44

J. Nordling, “Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia,” BJU Int, vol. 95, no. 7, pp. 1006–12, 2005.

  Deutsche Version: Alfuzosin